Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Am Klopferspitz 19
82152 Planegg-Martinsried
Tel: +49. 89. 78 79 73 10
Web: http://www.chromotek.com/home/
Chromotek GmbH, a biotech spin-off from the LMu Munich founded in 2008, aims to establish Chromobodies®, (which are highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications), as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. on the basis of its technology (patent pending). The team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here
